Foliglurax
Foliglurax (developmental code names PXT-002331, DT2331) is a positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR 4 ), which is under development by Prexton Therapeutics for the treatment of Parkinson's disease.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Foliglurax (developmental code names PXT-002331, DT2331) is a positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR 4 ), which is under development by Prexton Therapeutics for the treatment of Parkinson's disease. It reached phase II clinical trials, but while it was found to be safe and showed some signs of clinical improvement, it failed to sufficiently distinguish itself from placebo to meet the study endpoints. ic form of foliglurax.
See also
List of investigational Parkinson's disease drugs
Text derived from https://en.wikipedia.org/w/index.php?oldid=1335374935 under CC BY-SA 4.0; modifications have been made.